Pharmaceutical products

Tender description

The HSE wishes to establish a national multi supplier contract for the provision of Directly Acting Antiviral (DAAs) medicines for use in provision of treatment for hepatitis C to patients across all genotypes in 2018. The National Hepatitis C Treatment Programme (NHCTP) aims to provide treatment to every person with hepatitis C over the coming years so that it is a rare disease in Ireland by 2026. There are approximately 30 000 people in Ireland living with hepatitis C. The NHCTP was established in 2015 in response to the Department of Health Report “A Public Health Plan for the Therapeutic Treatment of Hepatitis C”. The NHCTP has received an annual budget of EUR 30 000 000 for all programme activities since 2015 and the NHCTP is currently planning treatment for 2018 within budget. This tender process is to cover patients initiating Hepatitis C treatment up to and including 28.2.2019. The HSE wishes to establish a national multi supplier contract for the provision of Directly Acting Antiviral (DAAs) medicines for use in provision of treatment for hepatitis C to patients across all genotypes in 2018. The National Hepatitis C Treatment Programme (NHCTP) aims to provide treatment to every person with hepatitis C over the coming years so that it is a rare disease in Ireland by 2026. There are approximately 30 000 people in Ireland living with hepatitis C. The NHCTP was established in 2015 in response to the Department of Health Report “A Public Health Plan for the Therapeutic Treatment of Hepatitis C”. The NHCTP has received an annual budget of EUR 30 000 000 for all programme activities since 2015 and the NHCTP is currently planning treatment for 2018 within budget. This tender process is to cover patients initiating Hepatitis C treatment up to and including 28.2.019.